118 related articles for article (PubMed ID: 14965177)
1. Response to gefitinib in pericardial effusion due to lung cancer.
Kikuchi N; Satoh H; Kodama T; Haraguchi N; Sekizawa K
Acta Medica (Hradec Kralove); 2003; 46(4):215-6. PubMed ID: 14965177
[TBL] [Abstract][Full Text] [Related]
2. [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
Madelaine J; Cadranel J; Zalcman G
Rev Mal Respir; 2004 Nov; 21(5 Pt 1):881-5. PubMed ID: 15622331
[No Abstract] [Full Text] [Related]
3. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Kelly K; Averbuch S
Semin Oncol; 2004 Feb; 31(1 Suppl 1):93-9. PubMed ID: 14981586
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
Araki J; Okamoto I; Suto R; Ichikawa Y; Sasaki J
Lung Cancer; 2005 Apr; 48(1):141-4. PubMed ID: 15777982
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
7. Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.
Kubo A; Koh Y; Kawaguchi T; Isa S; Okamoto I; Fukuoka J; Kusunoki Y; Kitaichi M; Takada M; Nakagawa K
Intern Med; 2011; 50(7):745-8. PubMed ID: 21467709
[TBL] [Abstract][Full Text] [Related]
8. Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Fujiwara K; Kiura K; Ueoka H; Tabata M; Hamasaki S; Tanimoto M
Lung Cancer; 2003 Apr; 40(1):73-6. PubMed ID: 12660009
[TBL] [Abstract][Full Text] [Related]
9. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
[No Abstract] [Full Text] [Related]
10. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
Vansteenkiste J
Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib--a novel targeted approach to treating cancer.
Herbst RS; Fukuoka M; Baselga J
Nat Rev Cancer; 2004 Dec; 4(12):956-65. PubMed ID: 15573117
[TBL] [Abstract][Full Text] [Related]
12. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.
Chang GC; Yang TY; Chen KC; Yin MC; Wang RC; Lin YC
J Clin Oncol; 2004 Nov; 22(22):4646-8. PubMed ID: 15542815
[No Abstract] [Full Text] [Related]
13. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
Baselga J
J Clin Oncol; 2002 May; 20(9):2217-9. PubMed ID: 11980990
[No Abstract] [Full Text] [Related]
14. Gefitinib: a new agent in palliative care.
Prommer E
Am J Hosp Palliat Care; 2004; 21(3):222-7. PubMed ID: 15188923
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
Liam CK; Pang YK; Leow CH
Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
[TBL] [Abstract][Full Text] [Related]
16. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.
Moiseyenko VM; Procenko SA; Levchenko EV; Barchuk AS; Moiseyenko FV; Iyevleva AG; Mitiushkina NV; Togo AV; Semionov II; Ivantsov AO; Matsko DE; Imyanitov EN
Onkologie; 2010; 33(5):231-8. PubMed ID: 20502057
[TBL] [Abstract][Full Text] [Related]
17. Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: a case report.
Ko HW; Tsai YH; Yu CT; Huang CY; Chen CH
Chang Gung Med J; 2008; 31(6):606-11. PubMed ID: 19241901
[TBL] [Abstract][Full Text] [Related]
18. The role of gefitinib in lung cancer treatment.
Giaccone G
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4233s-4237s. PubMed ID: 15217964
[TBL] [Abstract][Full Text] [Related]
19. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
20. Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.
Van Zandwijk N; Baas P
Suppl Tumori; 2002; 1(4):S37-8. PubMed ID: 12415815
[No Abstract] [Full Text] [Related]
[Next] [New Search]
